Ovid Therapeutics Appoints Dr. Jerome B. Zeldis to Its Scientific Advisory Board

New York, NY – October 8, 2015 – (Business Wire) – Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, announced today the appointment to its Scientific Advisory Board (SAB) of Jerome B. Zeldis, M.D., Ph.D., Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation.

Dr. Zeldis is noted for his exceptional and successful experience in drug development. Prior to his current role at Celgene, Dr. Zeldis has served as Celgene’s Senior Vice President of Clinical Research and Medical Affairs. Prior to joining Celgene in 1997, Dr. Zeldis was Associate Director of Clinical Research at Sandoz Research Institute where he helped develop Zelnorm® (tegaserod) and Director of Medical Development at Janssen Pharmaceutical Research Institute where he worked on Prepulsid® (cisapride). He currently serves as Chairman of the board of Semorex Corporation and has additional board positions at Alliqua, Bionor Pharma, PTC Therapeutics, Soligenix, and Trek Therapeutics. He was Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School, and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received BA and MS degrees from Brown University, and M Phil, MD, and PhD degrees from Yale University.

“We are delighted and privileged to welcome Jerry to our Scientific Advisory Board,” said Dr. Jeremy Levin, Chief Executive Officer and Chairman of Ovid. “Jerry’s advice and insight will be extremely valuable as we enter the clinic.”

Dr. Zeldis commented, “Ovid is pursuing an ambitious approach of tackling rare neurological diseases with significant unmet needs. With this goal, the company has assembled a world-class leadership and is employing a science-based approach to target new pathways that are involved in these diseases. I look forward to working closely with Ovid’s team.”

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a privately held, New York-based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid focuses on patients and their unmet medical needs. Using the significant operational, product development, and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development. Ovid recently completed a substantially oversubscribed $75 Million Series B financing led by Fidelity Management and Research Company and including Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates (on behalf of certain clients), Redmile Group, and Cormorant Asset Management, as well as additional blue chip mutual funds and leading life sciences investors.

For more information on Ovid, please visit http://ovidrx.com.


Burns McClellan, on behalf of Ovid Therapeutics
Justin Jackson, 212-213-0006, ext. 327